Droxidopa Capsule
Product Images NDC 82249-551

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Droxidopa (NDC 82249-551). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Civicascript Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Droxi-100 mg-90 Cont (Droxi 100 mg 90 Cont)

Label for Droxidopa Capsules 100 mg oral capsules, containing 90 capsules per bottle. Distributed by CivicaScript LLC in Lehi, Utah, and manufactured by Alkem Laboratories Ltd, Mumbai, India. Label includes dosage information, storage instructions, warnings, a QR code for more information, and barcodes.*

FDA Label Image

Droxi-200 mg-90 Cont (Droxi 200 mg 90 Cont)

Label for Droxidopa Capsules 200 mg, oral capsules supplied in a 90-count package by CivicaScript LLC. The label includes dosage information, storage instructions, distributor and manufacturer details, a QR code linking to more product information, and barcodes for scanning.*

FDA Label Image

Droxi-300 mg-90 Cont (Droxi 300 mg 90 Cont)

Label for Droxidopa Capsules 300 mg, containing 90 capsules per container. The label states the active ingredient strength and includes storage instructions, warnings, and distribution and manufacturing information. It is distributed by CivicaScript LLC and manufactured by Alkem Laboratories Ltd., Mumbai, India. The label also features a barcode and QR code for more information.*

FDA Label Image

Droxi01 (Droxi01)

Chemical structure of Droxidopa showing its molecular components, including hydroxyl groups, an amino group, and carboxyl group attached to a benzene ring.*

FDA Label Image

Droxi02 (Droxi02)

A line graph showing the mean change in dizziness over 8 weeks in a double-blind treatment phase comparing Droxidopa and placebo groups. The y-axis represents mean change in dizziness, and the x-axis represents weeks. The Droxidopa group shows a greater decrease in dizziness early in treatment compared to placebo, with data points and error bars displayed. A statistically significant difference is noted at week 1 (p<0.05).*

FDA Label Image

Droxi03 (Droxi03)

A bar chart showing the percentage of subjects on the y-axis and improvement in OHSA Question 1 on the x-axis, comparing placebo with droxidopa. The chart includes data bars for placebo and droxidopa groups, with improvement scores ranging from -8 to 8, and arrows indicating 'Worse' to the left and 'Better' to the right.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.